Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 887 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Climara Clear all
Completed Phase 3 Interventional Results available

Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy

NCT02770365
View directory record Official record
Conditions
Atrophy
Interventions
estrace cream (Perrigo), estrace cream (Reference), Placebo cream
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and/or Metastatic Kidney Cancer

NCT00003584
View directory record Official record
Conditions
Kidney Cancer
Interventions
estramustine phosphate sodium, prednisone, vinorelbine tartrate
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
Up to 120 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 21, 2026, 5:25 PM EDT
Terminated Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant

NCT02374099
View directory record Official record
Conditions
Breast Neoplasms
Interventions
CC-486, Fulvestrant
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Chandler, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2018 · Synced Oct 21, 2026, 5:25 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Evaluating the Roles of Estrogen and Progesterone in Heart Metabolism

NCT00565916
View directory record Official record
Conditions
Postmenopausal Syndrome
Interventions
Estrogen, Progesterone, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
55 Years to 75 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms

NCT01418209
View directory record Official record
Conditions
Hot Flashes, Menopause, Vasomotor Disturbance
Interventions
Low-dose 17-ß-estradiol with progesterone taper, Venlafaxine XR, Placebo
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
40 Years to 62 Years · Female only
Enrollment
339 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
4
States / cities
Boston, Massachusetts • Chestnut Hill, Massachusetts • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2014 · Synced Oct 21, 2026, 5:25 PM EDT
Completed No phase listed Observational

Combined Hormone Replacement in Menstrually-Related Mood Disorders

NCT00005011
View directory record Official record
Conditions
Premenstrual Syndrome, Depression
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Comparing Two Manufacturing Processes for Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg (LNG/EE) in Healthy, Cycling Women

NCT00319163
View directory record Official record
Conditions
Healthy
Interventions
levonorgestrel/ethinyl estradiol
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2009 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

NCT03213457
View directory record Official record
Conditions
Endometriosis
Interventions
Estradiol/Norethindrone Acetate, Placebo for Elagolix, Elagolix, Placebo for E2/NETA
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
188
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 140 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 21, 2026, 5:25 PM EDT
Recruiting Phase 2 Interventional

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

NCT07368998
View directory record Official record
Conditions
Breast Cancer
Interventions
Inavolisib, Fulvestrant
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Los Angeles, California • Jacksonville, Florida • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis

NCT01044498
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Ortho-Novum® 1/35
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 44 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
6
States / cities
Little Rock, Arkansas • Beverly Hills, California • Ormond Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2013 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Phase 1 Interventional

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

NCT03554044
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma
Interventions
Anastrozole, Exemestane, Fulvestrant, Letrozole, Paclitaxel, Talimogene Laherparepvec, Tamoxifen, Nab paclitaxel, Gemcitabine, Carboplatin
Drug · Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 21, 2026, 5:25 PM EDT
Terminated Phase 2 Interventional Results available

Fulvestrant in Treating Patients With Recurrent Prostate Cancer

NCT00217464
View directory record Official record
Conditions
Prostate Cancer
Interventions
fulvestrant
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Phase 2 Interventional

Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

NCT03781063
View directory record Official record
Conditions
Locally Advanced or Metastatic Breast Cancer
Interventions
Lasofoxifene, Fulvestrant
Drug
Lead sponsor
Sermonix Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
42
States / cities
Phoenix, Arizona • Yuma, Arizona • Duarte, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Phase 2 Interventional Results available

Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

NCT01142401
View directory record Official record
Conditions
Metastatic Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Bortezomib, Fulvestrant, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
21
States / cities
Farmington, Connecticut • New Haven, Connecticut • Weston, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Oct 21, 2026, 5:25 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

A Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis

NCT00816556
View directory record Official record
Conditions
Atrophic Vaginitis
Interventions
Estriol, Estradiol valerate, Vanicream Lite
Drug
Lead sponsor
Maire Mac Bride
Other
Eligibility
40 Years to 75 Years · Female only
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Phase 3 Interventional

Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment

NCT05894954
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia, Mild
Interventions
Precision Medicine Approach, Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises, Standard-of-Care, Lifestyle including diet, exercise, stress management
Dietary Supplement · Combination Product · Behavioral
Lead sponsor
Alzheimer's Prevention and Reversal Project, Inc.
Other
Eligibility
45 Years to 76 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Folsom, California • San Rafael, California • Walnut Creek, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 21, 2026, 5:25 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Oral Contraceptive Ethinyl Estradiol Dose Effect on Postpartum Depression and Sexual Functioning Scales

NCT02210702
View directory record Official record
Conditions
Postpartum Depressive Mood, Postpartum Sexual Function
Interventions
Ethinyl Estradiol 35mcg/Norethindrone 1mg, Ethinyl Estradiol 20mcg/Norethindrone 1mg
Drug
Lead sponsor
The Jones Institute
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer

NCT00003394
View directory record Official record
Conditions
Prostate Cancer
Interventions
carboplatin, endocrine-modulating drug therapy, estramustine phosphate sodium, goserelin acetate, leuprolide acetate, paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Pregnancy-associated Hormones on THC Metabolism in Women

NCT04374773
View directory record Official record
Conditions
Pregnancy Related, Cannabis Use
Interventions
Dronabinol
Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)

NCT06783192
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Interventions
MK-8527, LNG/EE
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 21, 2026, 5:25 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Androgen Blockade and Progesterone Augmentation of Gonadotropin Secretion

NCT04597099
View directory record Official record
Conditions
PCOS, Polycystic Ovary Syndrome
Interventions
Micronized progesterone, Placebo, Flutamide, Estradiol patch
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Do Oral Contraceptives Protect Against ACL Injuries in Female Athletes

NCT04899778
View directory record Official record
Conditions
Ligament Injury
Interventions
Oral Contraceptive Pill, norethindrn a-e estradiol-iron
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reproductive Capacity and Iron Burden in Thalassemia

NCT02308904
View directory record Official record
Conditions
THALASSEMIA MAJOR
Interventions
Blood Draw/Semen Exam, Retrospective data/Chart Review/Relevant Clinical Results, Pituitary MRI
Other
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
12 Years and older
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Phase 1Phase 2 Interventional

Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma

NCT00038168
View directory record Official record
Conditions
Prostate Cancer
Interventions
Estramustine, Taxol
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 21, 2026, 5:25 PM EDT